HK1162037A1 - Glucagon-like peptide-1 analogue and use thereof -1 - Google Patents

Glucagon-like peptide-1 analogue and use thereof -1

Info

Publication number
HK1162037A1
HK1162037A1 HK12102503.2A HK12102503A HK1162037A1 HK 1162037 A1 HK1162037 A1 HK 1162037A1 HK 12102503 A HK12102503 A HK 12102503A HK 1162037 A1 HK1162037 A1 HK 1162037A1
Authority
HK
Hong Kong
Prior art keywords
glucagon
analogue
peptide
Prior art date
Application number
HK12102503.2A
Other languages
English (en)
Chinese (zh)
Inventor
王印祥譚芬來胡邵京趙向東馬存波王燕萍沈曉燕丁列明胡雲雁曹紅龍偉
Original Assignee
貝達藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 貝達藥業股份有限公司 filed Critical 貝達藥業股份有限公司
Publication of HK1162037A1 publication Critical patent/HK1162037A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12102503.2A 2010-04-27 2012-03-13 Glucagon-like peptide-1 analogue and use thereof -1 HK1162037A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010156732 2010-04-27
CN201110078365 2011-03-30
PCT/CN2011/000764 WO2011134284A1 (zh) 2010-04-27 2011-04-29 胰高血糖素样肽-1类似物及其应用

Publications (1)

Publication Number Publication Date
HK1162037A1 true HK1162037A1 (en) 2012-08-17

Family

ID=44860821

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102503.2A HK1162037A1 (en) 2010-04-27 2012-03-13 Glucagon-like peptide-1 analogue and use thereof -1

Country Status (11)

Country Link
US (1) US8951959B2 (pt)
EP (1) EP2565205B1 (pt)
AU (1) AU2011247824B2 (pt)
BR (1) BR112012027545B1 (pt)
CA (1) CA2797431C (pt)
ES (1) ES2548259T3 (pt)
HK (1) HK1162037A1 (pt)
RU (1) RU2531590C2 (pt)
SG (1) SG185066A1 (pt)
WO (1) WO2011134284A1 (pt)
ZA (1) ZA201208829B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2454282T3 (pl) 2009-07-13 2015-08-31 Zealand Pharma As Acylowane analogi glukagonu
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
PL2875043T3 (pl) 2012-07-23 2017-06-30 Zealand Pharma A/S Analogi glukagonu
FR2994848B1 (fr) 2012-08-30 2014-08-22 Univ Paris Curie Traitement de l'arthrose par les hormones incretines ou leurs analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP3057984B1 (en) 2013-10-17 2018-07-11 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
KR102310389B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
MX2017012864A (es) 2015-04-16 2018-06-12 Zealand Pharma As Analogo acilado del glucagon.
CN106928086B (zh) * 2015-12-31 2019-05-31 深圳翰宇药业股份有限公司 一种长链化合物的制备方法
WO2019193576A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2401276C2 (ru) * 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
EP1670515A2 (en) * 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN101665538A (zh) * 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
KR20070120112A (ko) * 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
ES2528496T3 (es) * 2010-05-17 2015-02-10 Betta Pharmaceuticals Co., Ltd. Nuevos análogos de péptido similar a glucagón, composición, y métodos de uso

Also Published As

Publication number Publication date
US8951959B2 (en) 2015-02-10
RU2012150108A (ru) 2014-06-10
BR112012027545A8 (pt) 2018-01-02
EP2565205A1 (en) 2013-03-06
CA2797431A1 (en) 2011-11-03
EP2565205A4 (en) 2013-09-11
WO2011134284A1 (zh) 2011-11-03
AU2011247824B2 (en) 2014-02-13
US20130053304A1 (en) 2013-02-28
RU2531590C2 (ru) 2014-10-20
BR112012027545A2 (pt) 2017-03-14
ZA201208829B (en) 2013-09-25
SG185066A1 (en) 2012-12-28
ES2548259T3 (es) 2015-10-15
BR112012027545B1 (pt) 2020-09-24
EP2565205B1 (en) 2015-07-01
CA2797431C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HK1162037A1 (en) Glucagon-like peptide-1 analogue and use thereof -1
AU2011247824A1 (en) Glucagon-like peptide-1 analogue and use thereof
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
HK1192879A1 (zh) 取代的 -苄基環烷基羧酸及其用途
ZA201208173B (en) Peptices and their use
EP2383283A4 (en) NOGGIN PEPTIDE AND ITS USE
HK1195736A1 (zh) 放射免疫偶聯物和它們的用途
EP2474555A4 (en) PEPTIDE DERIVED FROM WNT10 AND USE THEREOF
HRP20182083T1 (hr) Nova kombinacija i uporaba
PL2585509T3 (pl) Części powlekane i ich zastosowanie
GB2480515B (en) Lacquer composition and use thereof
HK1168363A1 (en) Novel peptide and use thereof
EP2660249A4 (en) PEPTIDE DERIVATIVE AND USE THEREOF
ZA201200260B (en) Polyphenylsulphone-polytetrafluroethylene compositions and use thereof
GB0905790D0 (en) Novel polypeptides and use thereof
HK1162526A1 (en) Glp-1 derivatives and uses thereof glp-1
EP2450374A4 (en) PEPTIDE AND ITS USE
EP2488179A4 (en) NRF2 HEMMER AND ITS USE
GB0902812D0 (en) Composition and use
GB0906703D0 (en) Excipients and their use
GB201006380D0 (en) Excipients and their use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230501